. . "Klinick\u00E9 hodnocen\u00ED nov\u00FDch l\u00E9\u010Div u vz\u00E1cn\u00FDch diagn\u00F3z v onkologii \u2013 sou\u010Dasn\u00E1 situace v Evrop\u011B a u n\u00E1s"@cs . "Cancer represents one of the main causes of death among diseases across the age spectrum. Tumors in children, however, represent less than 1% of the total number of cancers in the population and in terms of the definition of orphan diseases in Europe are all children's cancers considered as orphan diseases. This is the reason why the re\u00ACsearch and development of new agents against cancer in childhood stands outside of the main interest. Every year around 30,000 new cases of cancer in children and adolescents are diagnosed in the European Unioun (EU) and ap\u00ACproximately 80% of them achieve long-term remission using mainly conventional methods of treatment. However, almost 6,000 children and adolescents die every year of malignant tumors therefore cancer remains a major cause of morbidity and mortality. Consequently, there is a demand for new and safe drugs for children suffering from cancer which would lead to improved survival and to risk reduction of late adverse effects of cancer treatment."@en . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . "\u0160t\u011Brbov\u00E1, Sylva" . "14110" . . . "CZ - \u010Cesk\u00E1 republika" . "24325" . "Klinick\u00E9 hodnocen\u00ED nov\u00FDch l\u00E9\u010Div u vz\u00E1cn\u00FDch diagn\u00F3z v onkologii \u2013 sou\u010Dasn\u00E1 situace v Evrop\u011B a u n\u00E1s" . . "Klinick\u00E9 hodnocen\u00ED nov\u00FDch l\u00E9\u010Div u vz\u00E1cn\u00FDch diagn\u00F3z v onkologii \u2013 sou\u010Dasn\u00E1 situace v Evrop\u011B a u n\u00E1s"@cs . . "Kodytkov\u00E1, Daniela" . "Suppl 2" . . "I, P(ED2.1.00/03.0101), P(LM2011017), P(LM2013034)" . . "clinical evaluation; new drugs; orphan diseases in oncology"@en . "Clinical evaluation of new drugs against orphan diseases in oncology - the current situation in Europe and in our country"@en . "Klinick\u00E9 hodnocen\u00ED nov\u00FDch l\u00E9\u010Div u vz\u00E1cn\u00FDch diagn\u00F3z v onkologii \u2013 sou\u010Dasn\u00E1 situace v Evrop\u011B a u n\u00E1s" . . "N\u00E1dorov\u00E1 onemocn\u011Bn\u00ED p\u0159edstavuj\u00ED i nad\u00E1le jednu z hlavn\u00EDch p\u0159\u00ED\u010Din \u00FAmrt\u00ED mezi nemocemi nap\u0159\u00ED\u010D v\u011Bkov\u00FDm spektrem. N\u00E1dory u d\u011Bt\u00ED v\u0161ak p\u0159edstavuj\u00ED m\u00E9n\u011B ne\u017E 1 % z celkov\u00E9ho po\u010Dtu n\u00E1dor\u016F v populaci a z hlediska definice vz\u00E1cn\u00FDch onemocn\u011Bn\u00ED v Evrop\u011B jsou v\u0161echny d\u011Btsk\u00E9 zhoubn\u00E9 n\u00E1dory vz\u00E1cn\u00E1 onemocn\u011Bn\u00ED. Z tohoto d\u016Fvodu stoj\u00ED sp\u00ED\u0161e mimo hlavn\u00ED proud v\u00FDzkumu a v\u00FDvoje nov\u00FDch protin\u00E1dorov\u00FDch l\u00E9\u010Div. V EU je ka\u017Ed\u00FD rok diagnostikov\u00E1no kolem 30 000 nov\u00FDch n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED u d\u011Bt\u00ED a mladistv\u00FDch a p\u0159ibli\u017En\u011B 80 % z nich dosahuje dlouhodob\u00FDch remis\u00ED dominantn\u011B konven\u010Dn\u00EDmi metodami l\u00E9\u010Dby. Z\u00E1rove\u0148 v\u0161ak t\u00E9m\u011B\u0159 6 000 d\u011Bt\u00ED a adolescent\u016F ka\u017Ed\u00FD rok na zhoubn\u00E9 n\u00E1dory um\u00EDr\u00E1, a proto n\u00E1dory z\u016Fst\u00E1vaj\u00ED i nad\u00E1le velmi v\u00FDznamnou p\u0159\u00ED\u010Dinou morbidity i mortality. Z tohoto d\u016Fvodu trv\u00E1 popt\u00E1vka po nov\u00FDch a bezpe\u010Dn\u00FDch l\u00E9\u010Div\u00FDch p\u0159\u00EDpravc\u00EDch pro d\u011Bti s n\u00E1dory, kter\u00E9 by vedly ke zlep\u0161en\u00ED p\u0159e\u017Eit\u00ED d\u011Bt\u00ED se zhoubn\u00FDmi n\u00E1dory a z\u00E1rove\u0148 ke sn\u00ED\u017Een\u00ED rizika pozdn\u00EDch n\u00E1sledk\u016F onkologick\u00E9 p\u00E9\u010De."@cs . "RIV/00216224:14110/14:00078990" . . "0042-773X" . . "5"^^ . . "N\u00E1dorov\u00E1 onemocn\u011Bn\u00ED p\u0159edstavuj\u00ED i nad\u00E1le jednu z hlavn\u00EDch p\u0159\u00ED\u010Din \u00FAmrt\u00ED mezi nemocemi nap\u0159\u00ED\u010D v\u011Bkov\u00FDm spektrem. N\u00E1dory u d\u011Bt\u00ED v\u0161ak p\u0159edstavuj\u00ED m\u00E9n\u011B ne\u017E 1 % z celkov\u00E9ho po\u010Dtu n\u00E1dor\u016F v populaci a z hlediska definice vz\u00E1cn\u00FDch onemocn\u011Bn\u00ED v Evrop\u011B jsou v\u0161echny d\u011Btsk\u00E9 zhoubn\u00E9 n\u00E1dory vz\u00E1cn\u00E1 onemocn\u011Bn\u00ED. Z tohoto d\u016Fvodu stoj\u00ED sp\u00ED\u0161e mimo hlavn\u00ED proud v\u00FDzkumu a v\u00FDvoje nov\u00FDch protin\u00E1dorov\u00FDch l\u00E9\u010Div. V EU je ka\u017Ed\u00FD rok diagnostikov\u00E1no kolem 30 000 nov\u00FDch n\u00E1dorov\u00FDch onemocn\u011Bn\u00ED u d\u011Bt\u00ED a mladistv\u00FDch a p\u0159ibli\u017En\u011B 80 % z nich dosahuje dlouhodob\u00FDch remis\u00ED dominantn\u011B konven\u010Dn\u00EDmi metodami l\u00E9\u010Dby. Z\u00E1rove\u0148 v\u0161ak t\u00E9m\u011B\u0159 6 000 d\u011Bt\u00ED a adolescent\u016F ka\u017Ed\u00FD rok na zhoubn\u00E9 n\u00E1dory um\u00EDr\u00E1, a proto n\u00E1dory z\u016Fst\u00E1vaj\u00ED i nad\u00E1le velmi v\u00FDznamnou p\u0159\u00ED\u010Dinou morbidity i mortality. Z tohoto d\u016Fvodu trv\u00E1 popt\u00E1vka po nov\u00FDch a bezpe\u010Dn\u00FDch l\u00E9\u010Div\u00FDch p\u0159\u00EDpravc\u00EDch pro d\u011Bti s n\u00E1dory, kter\u00E9 by vedly ke zlep\u0161en\u00ED p\u0159e\u017Eit\u00ED d\u011Bt\u00ED se zhoubn\u00FDmi n\u00E1dory a z\u00E1rove\u0148 ke sn\u00ED\u017Een\u00ED rizika pozdn\u00EDch n\u00E1sledk\u016F onkologick\u00E9 p\u00E9\u010De." . . "Val\u00EDk, Dalibor" . . "RIV/00216224:14110/14:00078990!RIV15-MSM-14110___" . . . . "[C67BB31DD299]" . "4"^^ . "\u0160t\u011Brba, Jaroslav" . "Clinical evaluation of new drugs against orphan diseases in oncology - the current situation in Europe and in our country"@en . . . "60" . . . "Demlov\u00E1, Regina" . "6"^^ .